INC424
Total Payments
$544,878
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $544,878 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $544,878 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM (RUXCOVID) | Novartis Pharmaceuticals Corporation | $544,878 | 0 |
Top Doctors Receiving Payments for INC424
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Flushing, NY | $544,878 | 4 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $544,878
Product Information
- Type Drug
- Total Payments $544,878
- Total Doctors 0
- Transactions 4
About INC424
INC424 is a drug associated with $544,878 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $544,878 was paid across 4 transactions to 0 doctors.
The most common payment nature for INC424 is "Unspecified" ($544,878, 100.0% of total).
INC424 is associated with 1 research study, including "PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH COVID-19 ASSOCIATED CYTOKINE STORM (RUXCOVID)" ($544,878).